Drug
Lanreotide
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Other Targeted Agents |
| Group | Somatostatin analog |
| Mechanism of Action | Somatostatin analog |
| Half-life | 23-30 d |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Not radioprotective and at most weak/context-specific radiosensitization; principal RT-relevant role is SSTR2 upregulation for PRRT (Ning et al., Endocrine-Related Cancer, 2009; Adant et al., European Journal of Nuclear Medicine and Molecular Imaging, 2020). With negligible external-beam sensitization, no meaningful theoretical increase in in-field radiation adverse events is expected.
Data on this page refer exclusively to patients treated with
Lanreotide combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Somatostatin analog group page.